CompletedNot Applicable

Early-Onset Colorectal Cancer Recurrence

United States177 participantsStarted 2023-04-15

Plain-language summary

Survivors of early-onset colorectal cancer (diagnosed before age 50) may experience colorectal cancer recurrence several years after curative-intent treatments, but clinical guidelines provide unclear guidance on endoscopic surveillance. This study aims to predict recurrence-free survival and overall survival, in survivors of early-onset colorectal cancer, using a tumor-based molecular assay based on microRNA (ribonucleic acid)

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Stage I, II, or III colorectal cancer (TNM classification, 8th edition) diagnosed before the age of 50 * Received standard diagnostic, staging, and therapeutic procedures as per local guidelines, received stage-specific curative-intent resection (with or without systemic therapy, as appropriate) * Confirmed cancer-free survivors at the time of study inclusion Exclusion Criteria: * Hereditary colorectal cancer syndromes (identified through genetic testing) * Inflammatory bowel diseases * Lack of written informed consent

What they're measuring

Recurrence Free Survival

Timeframe: Up to 120 months

Trial details

NCT IDNCT06271980

SponsorCity of Hope Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-02-01

View on ClinicalTrials.gov More Colorectal Cancer Recurrent trials